Skip to content

688331.SH

RemeGen Co., Ltd.

SSE · Healthcare · Biotechnology · CN

CNY 96.83
+2.31%
Ask drillr

Year over year

Reported trailing growth

Revenue
+76.8%
EBITDA
—
EBIT
+195.7%
EPS
+191.5%
Free cash flow
+104.0%
Operating cash flow
+128.8%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
+61.5%
EBITDA
+181.2%
EBIT
+149.6%
Net income
+148.3%
EPS
+147.3%
Free cash flow
+89.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026